Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Dec 23;13(2):17-24.
doi: 10.17925/HI.2019.13.2.17. eCollection 2019.

A Review of the Ultrathin Orsiro Biodegradable Polymer Drug-eluting Stent in the Treatment of Coronary Artery Disease

James J Wu  1   2 , Joshua Ah Way  1 , David Brieger  1   2
Affiliations
Review

A Review of the Ultrathin Orsiro Biodegradable Polymer Drug-eluting Stent in the Treatment of Coronary Artery Disease

James J Wu et al. Heart Int. .

Abstract

Drug-eluting stents (DES) have revolutionised the treatment of coronary artery disease (CAD) in patients undergoing percutaneous coronary intervention. In recent years, there has been a focus on a new generation of DES, such as biodegradable polymer DES (BP-DES). This novel stent platform was developed with the hope of eliminating the risk of very late stent thrombosis associated with the current gold-standard durable polymer DES (DP-DES). Ultrathin Orsiro BP-DES (Biotronik, Bülach, Switzerland) are based on a cobalt-chromium stent platform that is coated with a bioresorbable polymer coating containing sirolimus. These devices have one of the thinnest struts available in the current market and have the theoretical benefit of reducing a chronic inflammatory response in the vessel wall. In 2019, the United States Food and Drug Administration (FDA) approved the use of Orsiro BP-DES in patients with CAD based on promising results in recent landmark trials, such as BIOFLOW V and BIOSTEMI. The aim of the present review article was to discuss the history of stent technology and the continued opportunities for improvements, focusing on the potential benefits of Orsiro BP-DES.

Keywords: Biodegradable polymer; Orsiro; coronary artery disease; drug-eluting stents.

PubMed Disclaimer

Conflict of interest statement

Disclosure: James J Wu, Joshua AH Way and David Brieger have nothing to declare in relation to this article.

Figures

Figure 1:
Figure 1:. Features of Orsiro biodegradable polymer drug-eluting stents
See this image and copyright information in PMC

References

    1. Nowbar AN, Gitto M, Howard JP. et al. Mortality from ischemic heart disease. Circ Cardiovasc Qual Outcomes. 2019;12:e005375. - PMC - PubMed
    1. Kobo O, Roguin A.. Orsiro: ultrathin bioabsorbable polymer sirolimus-eluting stent. Future Cardiol. 2019;15:295–300. - PubMed
    1. Chen D, Jepson N. Coronary stent technology: a narrative review. Med J Aust. 2016;205:277–81. - PubMed
    1. Mueller RL, Sanborn TA. The history of interventional cardiology: cardiac catheterization, angioplasty, and related interventions. Am Heart J. 1995;129:146–72. - PubMed
    1. Castaneda WR, Formanek A, Tadavarthy M. et al. The mechanism of balloon angioplasty. Radiology. 1990;135:565–71. - PubMed

LinkOut - more resources